{"id":19002,"date":"2022-05-24T14:02:09","date_gmt":"2022-05-24T05:02:09","guid":{"rendered":"http:\/\/mus.brc.riken.jp\/ja\/?page_id=19002"},"modified":"2022-05-24T14:02:09","modified_gmt":"2022-05-24T05:02:09","slug":"jun_2022_mm","status":"publish","type":"page","link":"http:\/\/mus.brc.riken.jp\/ja\/mouse_of_month\/jun_2022_mm","title":{"rendered":"\u304c\u3093\u7814\u7a76\u6ce8\u76ee\u306e\u56e0\u5b50 Meflin(Islr)\u6a5f\u80fd\u89e3\u6790\u30c4\u30fc\u30eb"},"content":{"rendered":"\n\n\n
\"RIKEN<\/td>\nJune 2022<\/span>
\nMouse of the Month<\/span><\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n
\n

\u304c\u3093\u7814\u7a76\u6ce8\u76ee\u306e\u56e0\u5b50 Meflin(Islr)\u6a5f\u80fd\u89e3\u6790\u30c4\u30fc\u30eb
\n<\/span><\/p>\n

\n
\nC57BL\/6-Islr<tm1a(EUCOMM)Wtsi>\/Ea (RBRC09446)<\/a>
\n
\nB6.129S6-Islr<tm1.1(cre\/ERT2)Mat> (RBRC11436)<\/a>
\n
\nB6.129S6-Islr<tm1.1(ZsGreen\/DTR\/cre)Mat> (RBRC11437)<\/a>
\n<\/h5>\n

\n\"Meflin\u967d\u6027\u7d30\u80de\u306e\u5897\u6b96\u3068\u75c5\u614b\u306e\u9032\u884c\"<\/a><\/p>\n

Meflin\u967d\u6027\u7d30\u80de\u306f\u6b63\u5e38\u7d44\u7e54\u3067\u306f\u8840\u7ba1\u306e\u5468\u56f2\u306b\u9593\u8449\u7cfb\u5e79\u7d30\u80de\u3042\u308b\u3044\u306f\u8840\u7ba1\u5468\u56f2\u7dda\u7dad\u82bd\u7d30\u80de\u3068\u3057\u3066\u5c11\u6570\u5b58\u5728\u3057\u3066\u3044\u307e\u3059\u3002\u304c\u3093\u3084\u708e\u75c7\u7b49\u306b\u3088\u308a\u7d44\u7e54\u304c\u640d\u50b7\u3092\u53d7\u3051\u308b\u3068\u3001Meflin\u967d\u6027\u7d30\u80de\u306f\u5897\u6b96\u3057\u3001\u304c\u3093\u3084\u7dda\u7dad\u5316\u75be\u60a3\u7b49\u306e\u75c5\u614b\u306e\u9032\u884c\u3092\u6291\u5236\u3059\u308b\u53ef\u80fd\u6027\u304c\u793a\u5506\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u4e00\u65b9\u3001\u75c5\u614b\u306e\u9032\u884c\u306b\u4f34\u3044\u3001Meflin\u967d\u6027\u7d30\u80de\u306e\u4e00\u90e8\u306fMeflin\u5f31\u967d\u6027\u301c\u9670\u6027\u306e\u7b4b\u7dda\u7dad\u82bd\u7d30\u80de\u306b\u5206\u5316\u3057\u3001\u75c5\u614b\u306e\u9032\u884c\u306b\u5bc4\u4e0e\u3059\u308b\u3053\u3068\u3082\u77e5\u3089\u308c\u3066\u3044\u307e\u3059\u3002\n<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n
Meflin(Islr: Immunoglobulin Superfamily Containing Leucine Rich Repeat)\u306f\u3001GPI(glycosylphosphatidylinositol)\u578b\u5206\u6ccc\u819c\u30bf\u30f3\u30d1\u30af\u8cea\u3067\u3059\u3002\u5bc4\u8a17\u8005\u306e\u698e\u672c\u5148\u751f\u3089\u306b\u3088\u3063\u3066\u3001\u672a\u5206\u5316\u306a\u9593\u8449\u7cfb\u5e79\u7d30\u80de\u3001\u7dda\u7dad\u82bd\u7d30\u80de\u306e\u5206\u5b50\u30de\u30fc\u30ab\u30fc\u3068\u3057\u3066\u540c\u5b9a\u3055\u308c\u307e\u3057\u305f\u3002\u304c\u3093\u7814\u7a76\u5206\u91ce\u306b\u304a\u3044\u3066\u306f\u3001\u304c\u3093\u6291\u5236\u6027\u306e\u304c\u3093\u95a2\u9023\u7dda\u7dad\u82bd\u7d30\u80de(CAF\uff1acancer-associated fibroblast)\u306e\u6a5f\u80fd\u30de\u30fc\u30ab\u30fc\u3068\u3057\u3066\u5831\u544a\u3055\u308c\u3066\u3044\u307e\u3059[1-4]\u3002\u3053\u308c\u307e\u3067\u306b\u3001Meflin\u306f\u5927\u8178\u304c\u3093\u3084\u81b5\u81d3\u304c\u3093\u7b49\u5404\u7a2e\u304c\u3093\u306b\u304a\u3044\u3066\u3001BMP\u30b7\u30b0\u30ca\u30eb\u7d4c\u8def\u7b49\u3092\u4ecb\u3057\u3066\u3001\u304c\u3093\u9032\u884c\u6291\u5236\u306b\u95a2\u4e0e\u3057\u3066\u3044\u308b\u3053\u3068\u304c\u660e\u3089\u304b\u306b\u306a\u3063\u3066\u304a\u308a\u3001\u65b0\u898f\u304c\u3093\u6cbb\u7642\u30bf\u30fc\u30b2\u30c3\u30c8\u3068\u3057\u3066\u6ce8\u76ee\u3092\u96c6\u3081\u3066\u3044\u307e\u3059[5-8]\u3002\u3059\u3067\u306bMeflin\u306e\u767a\u73fe\u3092\u5897\u5f37\u3057\u3001\u304c\u3093\u4fc3\u9032\u6027CAF\u3092\u304c\u3093\u6291\u5236\u6027CAF\u306b\u5909\u63db\u3055\u305b\u308b\u5316\u5408\u7269\u3068\u3057\u3066\u5408\u6210\u30ec\u30c1\u30ce\u30a4\u30c9AM80\u304c\u540c\u5b9a\u3055\u308c\u3001AM80\u3068\u6297\u304c\u3093\u5264\u306e\u4f75\u7528\u306e\u52b9\u679c\u306b\u95a2\u3059\u308b\u6cbb\u9a13\u3082\u958b\u59cb\u3055\u308c\u3066\u3044\u307e\u3059[9,10]\u3002\u7406\u7814BRC\u304b\u3089\u306f\u3001Meflin\u306e\u6a5f\u80fd\u89e3\u6790\u3001\u767a\u73fe\u30d1\u30bf\u30fc\u30f3\u306e\u89e3\u6790\u306b\u6709\u7528\u306a\u30c4\u30fc\u30eb\u3068\u3057\u3066\u3001Meflin KO\u30de\u30a6\u30b9(RBRC09446)\u3001Meflin \u30bf\u30e2\u30ad\u30b7\u30d5\u30a7\u30f3\u8a98\u5c0e\u578bCre\u30c9\u30e9\u30a4\u30d0\u30fc\u30de\u30a6\u30b9(RBRC11436)\u3001\u5185\u5728\u6027Meflin \u30d7\u30ed\u30e2\u30fc\u30bf\u30fc\u5236\u5fa1\u4e0b\u3067\u86cd\u5149\u30bf\u30f3\u30d1\u30af\u8ceaZsGreen\u3001DTR(Diphtheria toxin receptor)\u3001Cre\u9175\u7d20\u3092\u540c\u6642\u306b\u767a\u73fe\u3059\u308b\u30ec\u30dd\u30fc\u30bf\u30fc\u30de\u30a6\u30b9(RBRC11437)\u306e3\u7cfb\u7d71\u3092\u63d0\u4f9b\u53ef\u80fd\u3067\u3059\u3002Meflin\u304c\u95a2\u308f\u308b\u304c\u3093\u306e\u3088\u308a\u8a73\u7d30\u306a\u5206\u5b50\u30e1\u30ab\u30cb\u30ba\u30e0\u304c\u660e\u3089\u304b\u306b\u306a\u308b\u3053\u3068\u3067\u3001\u8fd1\u3044\u5c06\u6765\u3001\u81e8\u5e8a\u5206\u91ce\u3067\u306e\u5b9f\u7528\u5316\u304c\u5b9f\u73fe\u3059\u308b\u3053\u3068\u304c\u671f\u5f85\u3055\u308c\u307e\u3059\u3002\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Depositor<\/td>\n:<\/td>\n\u698e\u672c \u7be4 \u5148\u751f
\u540d\u53e4\u5c4b\u5927\u5b66\n<\/td>\n<\/tr>\n
Strain name<\/td>\n:<\/td>\nC57BL\/6-Islr<tm1a(EUCOMM)Wtsi>\/Ea\n<\/td>\n<\/tr>\n
RBRC No.<\/td>\n:<\/td>\nRBRC09446<\/td>\n<\/tr>\n
Strain name<\/td>\n:<\/td>\nB6.129S6-Islr<tm1.1(cre\/ERT2)Mat>\n<\/td>\n<\/tr>\n
RBRC No.<\/td>\n:<\/td>\nRBRC11436<\/td>\n
Strain name<\/td>\n:<\/td>\nB6.129S6-Islr<tm1.1(ZsGreen\/DTR\/cre)Mat>\n<\/td>\n<\/tr>\n
RBRC No.<\/td>\n:<\/td>\nRBRC11437<\/td>\n<\/tr>\n
References<\/td>\n:<\/td>\n[1]<\/td>\nMaeda K, Enomoto A, Hara A, Asai N, Kobayashi T, Horinouchi A, Maruyama S, Ishikawa Y, Nishiyama T, Kiyoi H, Kato T, Ando K, Weng L, Mii S, Asai M, Mizutani Y, Watanabe O, Hirooka Y, Goto H, Takahashi M.
\nIdentification of Meflin as a Potential Marker for Mesenchymal Stromal Cells.
\nSci Rep.<\/em> 2016 Feb 29;6:22288. <\/a><\/td>\n<\/tr>\n
[2]<\/td>\nMizutani Y, Kobayashi H, Iida T, Asai N, Masamune A, Hara A, Esaki N, Ushida K, Mii S, Shiraki Y, Ando K, Weng L, Ishihara S, Ponik SM, Conklin MW, Haga H, Nagasaka A, Miyata T, Matsuyama M, Kobayashi T, Fujii T, Yamada S, Yamaguchi J, Wang T, Woods SL, Worthley D, Shimamura T, Fujishiro M, Hirooka Y, Enomoto A, Takahashi M.
\nMeflin-Positive Cancer-Associated Fibroblasts Inhibit Pancreatic Carcinogenesis.
\nCancer Res.<\/em> 2019 Oct 15;79(20):5367-5381.<\/a><\/td>\n<\/tr>\n
[3]<\/td>\nMiyai Y, Esaki N, Takahashi M, Enomoto A.
\nCancer-associated fibroblasts that restrain cancer progression: Hypotheses and perspectives.
\nCancer Sci.<\/em> 2020 Apr;111(4):1047-1057.<\/a><\/td>\n<\/tr>\n
[4]<\/td>\nKobayashi H, Gieniec KA, Wright JA, Wang T, Asai N, Mizutani Y, Lida T, Ando R, Suzuki N, Lannagan TRM, Ng JQ, Hara A, Shiraki Y, Mii S, Ichinose M, Vrbanac L, Lawrence MJ, Sammour T, Uehara K, Davies G, Lisowski L, Alexander IE, Hayakawa Y, Butler LM, Zannettino ACW, Din MO, Hasty J, Burt AD, Leedham SJ, Rustgi AK, Mukherjee S, Wang TC, Enomoto A, Takahashi M, Worthley DL, Woods SL.
\nThe Balance of Stromal BMP Signaling Mediated by GREM1 and ISLR Drives Colorectal Carcinogenesis.
\nGastroenterology.<\/em>2021 Mar;160(4):1224-1239.e30.<\/a><\/td>\n<\/tr>\n
[5]<\/td>\nMiyai Y, Sugiyama D, Hase T, Asai N, Taki T, Nishida K, Fukui T, Chen-Yoshikawa TF, Kobayashi H, Mii S, Shiraki Y, Hasegawa Y, Nishikawa H, Ando Y, Takahashi M, Enomoto A.
\nMeflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade.
\nLife Sci Alliance.<\/em> 2022 Mar 2;5(6):e202101230.<\/a><\/td>\n<\/tr>\n
[6]<\/td>\nHara A, Kobayashi H, Asai N, Saito S, Higuchi T, Kato K, Okumura T, Bando YK, Takefuji M, Mizutani Y, Miyai Y, Saito S, Maruyama S, Maeda K, Ouchi N, Nagasaka A, Miyata T, Mii S, Kioka N, Worthley DL, Murohara T, Takahashi M, Enomoto A.
\nRoles of the Mesenchymal Stromal\/Stem Cell Marker Meflin in Cardiac Tissue Repair and the Development of Diastolic Dysfunction.
\nCirc Res.<\/em> 2019 Aug 2;125(4):414-430.<\/a><\/td>\n<\/tr>\n
[7]<\/td>\nHara A, Kato K, Ishihara T, Kobayashi H, Asai N, Mii S, Shiraki Y, Miyai Y, Ando R, Mizutani Y, Iida T, Takefuji M, Murohara T, Takahashi M, Enomoto A.
\nMeflin defines mesenchymal stem cells and\/or their early progenitors with multilineage differentiation capacity.
\nGenes Cells.<\/em> 2021 Jul;26(7):495-512.<\/a><\/td>\n<\/tr>\n
[8]<\/td>\nNakahara Y, Hashimoto N, Sakamoto K, Enomoto A, Adams TS, Yokoi T, Omote N, Poli S, Ando A, Wakahara K, Suzuki A, Inoue M, Hara A, Mizutani Y, Imaizumi K, Kawabe T, Rosas IO, Takahashi M, Kaminski N, Hasegawa Y.
\nFibroblasts positive for meflin have anti-fibrotic properties in pulmonary fibrosis.
\nEur Respir J.<\/em> 2021 Dec 23;58(6):2003397.<\/a><\/td>\n<\/tr>\n
[9]<\/td>\nMizutani Y, Iida T, Ohno E, Ishikawa T, Kinoshita F, Kuwatsuka Y, Imai M, Shimizu S, Tsuruta T, Enomoto A, Kawashima H, Fujishiro M.
\nSafety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I\/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma.
\nBMC Cancer.<\/em> 2022 Feb 24;22(1):205.<\/a><\/td>\n<\/tr>\n
[10]<\/td>\nIida T, Mizutani Y, Esaki N, Ponik SM, Burkel BM, Weng L, Kuwata K, Masamune A, Ishihara S, Haga H, Kataoka K, Mii S, Shiraki Y, Ishikawa T, Ohno E, Kawashima H, Hirooka Y, Fujishiro M, Takahashi M, Enomoto A.
\nPharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics.
\nOncogene.<\/em> 2022 Apr 13.<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n
June 2022
\nSaori Mizuno, Ph.D.
\nContact: Experimental Animal Division, RIKEN BioResource Research Center (animal.brc@riken.jp)<\/a>
\nAll materials contained on this site may not be reproduced, distributed, displayed, published or broadcast without the prior permission of the owner of that content.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

June 2022 Mouse of the Month \u304c\u3093\u7814\u7a76\u6ce8\u76ee\u306e\u56e0\u5b50 Meflin(Islr)\u6a5f\u80fd\u89e3\u6790\u30c4\u30fc\u30eb C57BL\/6-Islr<tm1a(EUCOMM)Wtsi>\/Ea (RBRC09446) B6.129S6-Islr<tm1.1(cre\/ERT2)Mat> (RBRC11436) B6.129S6-Islr<tm1.1(ZsGreen\/DTR\/cr […]<\/p>\n","protected":false},"author":19,"featured_media":0,"parent":198,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","_seopress_robots_follow":"","_seopress_robots_imageindex":"","_seopress_robots_snippet":"","_seopress_robots_primary_cat":"","_seopress_robots_breadcrumbs":"","_seopress_robots_freeze_modified_date":"","_seopress_robots_custom_modified_date":"","_seopress_robots_canonical":"","_seopress_social_fb_title":"","_seopress_social_fb_desc":"","_seopress_social_fb_img":"","_seopress_social_fb_img_attachment_id":0,"_seopress_social_fb_img_width":0,"_seopress_social_fb_img_height":0,"_seopress_social_twitter_title":"","_seopress_social_twitter_desc":"","_seopress_social_twitter_img":"","_seopress_social_twitter_img_attachment_id":0,"_seopress_social_twitter_img_width":0,"_seopress_social_twitter_img_height":0,"_seopress_redirections_value":"","_seopress_redirections_enabled":"","_seopress_redirections_enabled_regex":"","_seopress_redirections_logged_status":"both","_seopress_redirections_param":"","_seopress_redirections_type":301,"_seopress_analysis_target_kw":"","footnotes":"","_wp_rev_ctl_limit":""},"class_list":["post-19002","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"http:\/\/mus.brc.riken.jp\/ja\/wp-json\/wp\/v2\/pages\/19002","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/mus.brc.riken.jp\/ja\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/mus.brc.riken.jp\/ja\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/mus.brc.riken.jp\/ja\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"http:\/\/mus.brc.riken.jp\/ja\/wp-json\/wp\/v2\/comments?post=19002"}],"version-history":[{"count":1,"href":"http:\/\/mus.brc.riken.jp\/ja\/wp-json\/wp\/v2\/pages\/19002\/revisions"}],"predecessor-version":[{"id":19003,"href":"http:\/\/mus.brc.riken.jp\/ja\/wp-json\/wp\/v2\/pages\/19002\/revisions\/19003"}],"up":[{"embeddable":true,"href":"http:\/\/mus.brc.riken.jp\/ja\/wp-json\/wp\/v2\/pages\/198"}],"wp:attachment":[{"href":"http:\/\/mus.brc.riken.jp\/ja\/wp-json\/wp\/v2\/media?parent=19002"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}